 |
 |
This is a multi-part message in MIME format. --------------643B69A03C0C Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013 --------------643B69A03C0C Content-Type: message/rfc822 Content-Transfer-Encoding: 7bit Content-Disposition: inline Message-ID: <[log in to unmask]> Date: Thu, 12 Nov 1998 09:03:44 -0800 From: "J. R. Bruman" <[log in to unmask]> Reply-To: [log in to unmask] X-Mailer: Mozilla 3.0C-NC320 (Win95; U) MIME-Version: 1.0 To: Parkinson's Information Exchange <[log in to unmask]> Subject: Re: New Selegiline-Study Results References: <000101be0da2$d4310d00$f8605bcc@ex001963> Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit SJS wrote: > At the PharminfoBytes website, I just read the results of a new study about > suspected links between selegiline and the risk of mortality, and you might > want to read it. The web-adress for the article is > http://pharminfo.com/pubs/msb/seleg252.html . I don't know how "new" the referenced study is (haven't had time to read the web page carefully) but the original announcement provoked a rather acrimonious debate, documented in the scientific journals for the past year or two. Some attacked the analysis method of the British group, and the counterpart U.S. group has reported that their 13-year followup of the 800+ DATATOP subjects doesn't show any significant mortality increase. Cheers, Joe -- J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks, CA 91403-5013 --------------643B69A03C0C--